drugset / Trial / NCT02184247

Bioavailability of Two Sustained-release Theophylline Products in Healthy Males

NCT02184247

Phase 1 Completed 22 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to compare the bioavailability of 350 mg Bronchoretard® - a sustained-release theophylline (anhydrous) product with respect to the reference product, Theo Dur® 300 mg theophylline anhydrous (sustained-release product) by comparing the rate and extent of absorption of theophylline based on both single and multiple-dose profiles.

Timeline

Start
1998-04
Primary completion
1998-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Theophylline Small molecule 300 mg
Subject Theophylline Small molecule 350 mg

Indications

No indication recorded.